this study aims to comprehensively evaluate the efficacy and safety profiles of rivaroxaban and warfarin during the initial postoperative period following surgical bioprosthetic valve in patients.
Aged between 18 and 80 years
Patients who underwent successful surgical bioprosthetic valve replacement or repair to either the mitral, aortic position or both
Signed informed consent
Aged below 18 or over 80 years
Mechanical heart valves (MHV)
Bioprosthetic valve transcatheter valve replacement (TAVR)
Hemorrhage risk-related criteria